Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor

Journal of Translational Medicine

Methodology

Mark E Dudley¹  Robert PT Somerville¹  Laura Devillier¹  Steven A Rosenberg¹  Maria R Parkhurst¹ 

[1] Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;

关键词: Human;    T Cells;    Tumor Immunity;    T Cell Receptors;    Adoptive Immunotherapy;   

DOI  :  10.1186/1479-5876-10-69

 received in 2011-11-08, accepted in 2012-04-04,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundTo simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.MethodsWe have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.ResultsTIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.ConclusionsThe WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under GMP conditions, and provides an alternate approach to cell generation for ACT protocols.

【 授权许可】

Unknown   
© Somerville et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.